(MENAFN- GlobeNewsWire - Nasdaq) Opportunities span personalized therapies, biosimilars, diagnostics and research, as protein engineering, antibodies, enzymes, high-purity production and localized supply chains gain traction.Dublin, Sept. 14, 2026 (GLOBE NEWSWIRE) -- "Recombinant Proteins Market Report 2026" has been added to ResearchAndMarkets.com's offering.
Recombinant Proteins Market to Reach $4.84 Billion by 2030 as Personalized Medicine and Biologics Demand Accelerate
The global recombinant proteins market is experiencing rapid growth, supported by expanding biologics development, rising demand for protein-based diagnostics and increasing adoption of advanced therapeutic technologies. The market grew from $2.55 billion in 2025 to an estimated $2.89 billion in 2026, representing a compound annual growth rate (CAGR) of 13.5%. Historical growth has been supported by the increasing prevalence of autoimmune and chronic diseases, the widespread use of recombinant insulin and continued improvements in protein expression systems.
The recombinant proteins market is projected to reach $4.84 billion by 2030, expanding at a CAGR of 13.7% from 2026. Key market growth drivers include the adoption of next-generation biologics, rising investment in biomanufacturing facilities, expanding biosimilar development and greater use of recombinant proteins in scientific research. Growing demand for personalized therapeutics is also expected to create significant opportunities for biotechnology and pharmaceutical companies. Prominent recombinant proteins market trends include increased production of therapeutic antibodies, rising demand for recombinant enzymes, broader use of protein engineering techniques and investment in high-purity protein expression and biologics manufacturing capacity.
Personalized medicine is expected to remain a major catalyst for recombinant protein market growth. Advances in genomics, molecular profiling and healthcare data analytics are enabling the development of treatments aligned with individual genetic and molecular characteristics. Recombinant proteins play an important role in targeted therapeutic development by supporting greater treatment precision, improved clinical effectiveness and the potential reduction of adverse effects. According to the Personalized Medicine Coalition, the US Food and Drug Administration approved 16 new personalized treatments for patients with rare diseases in 2023, compared with six approvals in 2022. The increase highlights the growing importance of precision therapeutics and the technologies used to develop them.
Strategic partnerships are becoming increasingly important across the recombinant proteins industry as organizations combine development, manufacturing and commercialization capabilities. In October 2023, ARTES Biotechnology GmbH entered into a strategic partnership and co-marketing agreement with Basic Pharma. The collaboration focuses on developing and producing non-GMP recombinant proteins while establishing a more streamlined supply chain. The partnership is intended to shorten development timelines and accelerate the introduction of new pharmaceutical products, reflecting the industry's broader emphasis on manufacturing efficiency and faster time to market.
Merger and acquisition activity is also strengthening recombinant protein portfolios and rare disease pipelines. In May 2024, Sanofi acquired Inhibrx Inc. for approximately $1.7 billion, together with a contingent value right. The transaction gave Sanofi access to SAR447537, a differentiated human recombinant protein therapeutic designed for the treatment of alpha-1 antitrypsin deficiency. The acquisition expands Sanofi's capabilities in rare diseases, enhances its biologics portfolio and supports further innovation in engineered protein therapeutics. It also demonstrates the strategic value of specialized recombinant protein assets within the global pharmaceutical industry.
North America was the largest region in the recombinant proteins market in 2025. The geographic regions covered by the market include Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. Countries covered include Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, the United Kingdom, the United States, Canada, Italy and Spain.
Markets Covered:
1) By Product: Antibodies; Cytokines; Virus Antigens; Enzymes; Recombinant Regulatory Proteins; Hormones; Other Products
2) By Application: Drug And Discovery Development; Therapeutics; Research; Other Applications
3) By End User: Pharmaceutical And Biotechnology Companies; Academic And Research Institutes; Diagnostic Laboratories; Other End Users
Subsegments:
1) By Antibodies: Monoclonal Antibodies; Polyclonal Antibodies
2) By Cytokines: Interleukins; Interferons; Tumor Necrosis Factors (TNFs)
3) By Virus Antigens: Viral Capsid Proteins; Envelope Proteins
4) By Enzymes: Restriction Enzymes; Polymerases; Ligases
5) By Recombinant Regulatory Proteins: Transcription Factors; Receptors
6) By Hormones: Insulin; Growth Hormones
7) By Other Products: Fusion Proteins; Peptide Therapeutics
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Key Attributes:
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Comments
No comment